News

Filter

Emergent considers options as Abbott ends drug R&D collaboration

30-12-2011

Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Emergent BioSolutions gets late-stage MAb cancer therapy from TenX BioPharma

09-06-2011

Emergent BioSolutions (NYSE: EBS) has acquired from fellow USA-based TenX BioPharma the rights to zanolimumab,…

BiotechnologyEmergent BioSolutionsLicensingOncologyPharmaceuticalTenX BioPharmazanolimumab

Emergent BioSolutions to buy Trubion Pharma for up to $135.5 million; reaffirms 2010 guidance

16-08-2010

US vaccine maker Emergent BioSolutions has entered into a definitive agreement to acquire Trubion Pharmaceuticals,…

BiotechnologyEmergent BioSolutionsImmunologicalsMergers & AcquisitionsOncologyPharmaceuticalTrubion PharmaceuticalsVaccines

Back to top